证券日报网讯 2月3日，科德数控在互动平台回答投资者提问时表示，公司若有定增计划，会依法依规 履行审议程序并及时对外披露。 （文章来源：证券日报） ...

Core Viewpoint - Youfa Group has announced the termination of its A-share issuance plan for 2024, which was initially aimed at raising up to 1 billion yuan for capacity expansion, working capital, and repaying bank loans [1][2]. Group 1: Termination of Fundraising Plan - The planned issuance was approved by the board and shareholders in late 2024 but was ultimately terminated due to the expiration of the authorization period and considerations of market conditions and company strategy [2]. - The company stated that the termination of the fundraising will not significantly impact its normal operations or shareholder interests [2]. Group 2: Financial Stability Concerns - The termination of the fundraising plan raises concerns about the potential pressure on Youfa Group's cash flow, especially given its rising debt levels [3]. - Youfa Group's debt-to-asset ratio has increased from 54.37% in 2021 to 71.44% by the third quarter of 2025, significantly higher than the industry average [4]. - The company's bank loan balance has also risen, reaching 70.56 billion yuan by mid-2024, with corresponding interest expenses fluctuating over the years [4]. Group 3: Performance Trends - Youfa Group's main products are steel pipes used in various sectors, including water supply, gas supply, and construction [5]. - The company has experienced fluctuating profits due to declining steel prices, reduced demand, and rising costs, with net profits dropping from 11.43 billion yuan in 2020 to 4.25 billion yuan in 2024 [6]. - However, in 2025, Youfa Group reported a significant rebound in profitability, with a net profit of 5.02 billion yuan in the first three quarters, marking a 399.25% year-on-year increase [7].

Core Viewpoint - The company NuoTai Bio (688076.SH) has been penalized by the China Securities Regulatory Commission (CSRC) for financial fraud and has officially been designated as ST (Special Treatment) due to its violations, which include fabricating financial data and misleading disclosures [1][3]. Group 1: Company Violations - NuoTai Bio was found to have falsely recognized 30 million yuan in revenue through fictitious technology transfers, inflating profits by 25.95 million yuan, which accounted for 20.6% of the disclosed amount [1]. - The company also fabricated significant content in its public offering documents, with the 2023 convertible bond prospectus continuing to use this false data, constituting a serious violation of issuance document integrity [1][3]. Group 2: Underwriter's Responsibility - Nanjing Securities (601990.SH), as the underwriter for NuoTai Bio, was deeply involved in its financing operations and failed to identify the discrepancies in the financial disclosures, despite confirming the accuracy of the information provided [3][6]. - The underwriter received a total of 66.3854 million yuan in underwriting fees for the IPO and an additional 5.66 million yuan for the convertible bond project, raising questions about its due diligence practices [3][6]. Group 3: Regulatory and Market Impact - Following the scandal, Nanjing Securities has faced scrutiny for its oversight quality, with over 40% of the 17 IPO and refinancing companies it has supervised in the past decade encountering issues such as financial fraud and disclosure violations [6]. - Despite achieving a record net profit of 1 billion yuan in 2024, Nanjing Securities reported an 11.6% decline in revenue in the first quarter of 2025, indicating potential weaknesses in its business performance [7]. Group 4: Future Outlook - NuoTai Bio's stock will be subject to additional risk warnings from the Shanghai Stock Exchange, but it does not currently face mandatory delisting due to major legal violations [8]. - Nanjing Securities' 5 billion yuan private placement plan has faced delays and scrutiny, with the validity of the plan extended to July 2026, leaving its future uncertain [8].